The patent infringement case against biotechnology firm Pacific Biosciences of California Inc. has been moved from a Delaware federal court to California. According to the judgement, there were insufficient reasons to support maintaining the case proceedings in Delaware.
Pacific Biosciences of California Inc., commonly known as PacBio, is a biotechnology company that’s profusely involved in the development of systems for gene sequencing. It’s alleged to have contravened an epigenetics patent, though details about the alleged breach or the owner of the patent remain obscure.
This case, like numerous other patent suits, understands the strategic importance of the chosen venue for litigation, which often influences the case’s process and outcome. Delaware has long been a favored hub for patent cases because of its much-touted speed and familiarity with complex patent issues. Nevertheless, this move underscores that the needs for venue alignment with a defendant’s primary place of operation or where the supposed violation purportedly occurred are becoming progressively significant.
This decision is representative of an ongoing trend in IP litigation, as courts increasingly realign patent cases to jurisdictions with more direct connections to the alleged infringements. This reassessment of jurisdictional aspects can potentially have a large impact on the litigation strategies of many corporations and legal firms.
For additional information on the case, refer to the original report available at Law360.